Drug intelligence / Profile preview

Girentuximab I-124

Development stage: Phase 3
Lead developer: Telix Pharmaceuticals
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Girentuximab I-124 is a radiolabeled chimeric monoclonal antibody designed for diagnostic imaging in oncology. It consists of the antibody girentuximab labeled with the radioisotope iodine-124 (I-124), enabling positron emission tomography (PET) imaging. The antibody specifically targets carbonic anhydrase IX (CAIX), a protein highly expressed on the surface of clear cell renal cell carcinoma (ccRCC) cells and other hypoxic tumor regions[6][7]. By binding to CAIX, girentuximab allows for noninvasive detection and characterization of ccRCC lesions using PET/CT scans[2][7]. The mechanism involves both high-affinity antigen binding and facilitation of immune-mediated cytotoxicity such as antibody-dependent cellular cytotoxicity (ADCC)[6][8]. Girentuximab I-124 is primarily developed as a diagnostic agent to improve preoperative identification and management of renal masses suspected to be ccRCC[5][7].

Brand names: Redectane
Other names: IODINE (124I) GIRENTUXIMAB

Targets

CA9 (Carbonic anhydrase IX)

Beyond the preview

Go deeper on Girentuximab I-124.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Girentuximab I-124.

Explore the full profile